skip to content

Roche’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes

Media

Media releases
view all

stay updated

get the latest news and updates to your inbox.